Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Your Diabetes Endocrine Nutrition Group, Inc.
mi
from
Mentor, OH
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Your Diabetes Endocrine Nutrition Group, Inc.
mi
from
Mentor, OH
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Chris Sholer, MD, PC
mi
from
Oklahoma City, OK
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Chris Sholer, MD, PC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Bend Memorial Clinic
mi
from
Bend, OR
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Bend Memorial Clinic
mi
from
Bend, OR
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Knoxville Kidney Center PLLC
mi
from
Knoxville, TN
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Knoxville Kidney Center PLLC
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Arlington Nephrology
mi
from
Arlington, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Arlington Nephrology
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
MW Clinical Research Center
mi
from
Beaumont, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
MW Clinical Research Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Padre Coast Clinical Research
mi
from
Corpus Christi, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Padre Coast Clinical Research
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Corsicana Medical Research
mi
from
Corsicana, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Corsicana Medical Research
mi
from
Corsicana, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Texas Tech University Health Sciences Center
mi
from
El Paso, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Texas Tech University Health Sciences Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
TVC Clinical Research
mi
from
Gonzales, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
TVC Clinical Research
mi
from
Gonzales, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Diagnostic Clinic of Houston
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Diagnostic Clinic of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Lakewood Family Practice
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Lakewood Family Practice
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Mercury Clinical Research
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Mercury Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Southwest Clinical Trials
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Southwest Clinical Trials
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Southwest Houston Research, Ltd
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Southwest Houston Research, Ltd
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
HMRI CCAT Pearland
mi
from
Pearland, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
HMRI CCAT Pearland
mi
from
Pearland, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Briggs Clinical Research, LLC
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Briggs Clinical Research, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Val R. Hansen, M.D.
mi
from
Bountiful, UT
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Val R. Hansen, M.D.
mi
from
Bountiful, UT
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Fletcher Allen Health Care
mi
from
Burlington, VT
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
University of Virginia
mi
from
Charlottesville, VA
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
University of Wisconsin
mi
from
Madison, WI
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
Zablocki VAMC
mi
from
Milwaukee, WI
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
Zablocki VAMC
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated:  1/12/2017
BC Diabetes
mi
from
Vancouver,
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Status: Enrolling
Updated: 1/12/2017
BC Diabetes
mi
from
Vancouver,
Click here to add this to my saved trials
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress® (Everolimus) Versus Rapamune® (Sirolimus) in Combination With Low Dose Neoral® (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin® (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.
Status: Enrolling
Updated:  1/23/2017
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress® (Everolimus) Versus Rapamune® (Sirolimus) in Combination With Low Dose Neoral® (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin® (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.
Status: Enrolling
Updated: 1/23/2017
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Knoxville, TN
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Exercise and Vascular Function in Chronic Kidney Disease
Exercise and Vascular Function in Chronic Kidney Disease
Status: Enrolling
Updated:  2/6/2017
Department of Kinesiology and Applied Physiology, University of Delaware
mi
from
Newark, DE
Exercise and Vascular Function in Chronic Kidney Disease
Exercise and Vascular Function in Chronic Kidney Disease
Status: Enrolling
Updated: 2/6/2017
Department of Kinesiology and Applied Physiology, University of Delaware
mi
from
Newark, DE
Click here to add this to my saved trials
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated:  2/8/2017
University of Alabama
mi
from
Birmingham, AL
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated: 2/8/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated:  2/8/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated: 2/8/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated:  2/8/2017
Hennepin County Medical Center
mi
from
Minneapolis, MN
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated: 2/8/2017
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated:  2/8/2017
The Mayo Clinic
mi
from
Rochester, MN
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated: 2/8/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated:  2/8/2017
University of Alberta
mi
from
Edmonton,
Genomics of Kidney Transplantation
Genomics of Kidney Transplantation
Status: Enrolling
Updated: 2/8/2017
University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Montefiore Medical Center
mi
from
New York, NY
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated:  2/22/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Status: Enrolling
Updated: 2/22/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
North American Research Institute
mi
from
Azusa, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
North American Research Institute
mi
from
Azusa, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
West Glendale Dialysis
mi
from
Glendale, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
West Glendale Dialysis
mi
from
Glendale, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
California Institute of Renal Research
mi
from
La Mesa, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
California Institute of Renal Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
Academic Medical Center
mi
from
Los Angeles, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
Academic Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
Nephrology Specialist Medical Group
mi
from
Orange, CA
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
Nephrology Specialist Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
Pines Clinical Research, Inc.
mi
from
Pembroke Pines, FL
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
Pines Clinical Research, Inc.
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
University of Kentucky
mi
from
Lexington, KY
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
Fresenius Medical Care North America MI
mi
from
Kalamazoo, MI
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
Fresenius Medical Care North America MI
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated:  3/7/2017
DaVita Clinical Research
mi
from
Minneapolis, MN
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).
Status: Enrolling
Updated: 3/7/2017
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials